In vitro and in vivo antibacterial activities of KRM-1648 and KRM-1657, new rifamycin derivatives.

doi:10.1128/AAC.38.5.1118

Back to search

Article

In vitro and in vivo antibacterial activities of KRM-1648 and KRM-1657, new rifamycin derivatives.

Antimicrobial agents and chemotherapy - 1 May 1994

Fujii K, Tsuji A, Miyazaki S, Yamaguchi K, Goto S

Abstract excerpt

The in vitro and in vivo antibacterial activities of the new rifamycin derivatives KRM-1648 and KRM-1657 were compared with those of rifampin. Rifabutin, ciprofloxacin, and clarithromycin were also tested for reference. The respective MICs of KRM-1648 and KRM-1657 for 90% of the strains tested (M...

Topics

Animals
Antibiotics, Antitubercular
Bacteria
Bacterial Infections
Drug Resistance, Microbial
Male
Mice
Mice, Inbred ICR
Mutation
Rifampin
Rifamycins
Staphylococcal Infections
Staphylococcus aureus

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.